Trials / Completed
CompletedNCT00043966
Study of Lopinavir, Ritonavir, Tenofovir and Emtricitabine in HIV-Infected Antiretroviral Naïve Subjects
A Randomized, Open-Label Study of 800 Mg Lopinavir/200 Mg Ritonavir QD in Combination With Tenofovir and Emtricitabine Vs. 400 Mg Lopinavir /100 Mg Ritonavir BID in Combination With Tenofovir and Emtricitabine in HIV-Infected Antiretroviral Naïve Subjects
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 200 (planned)
- Sponsor
- Abbott · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to compare the safety, tolerability and antiviral activity between once-daily (QD) and twice-daily (BID) dosing of lopinavir/ritonavir and to further characterize the pharmacokinetics of once-daily dosing of lopinavir/ritonavir.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Lopinavir/ritonavir | |
| DRUG | Tenofovir DF | |
| DRUG | Emtricitabine |
Timeline
- Start date
- 2002-07-01
- First posted
- 2002-08-19
- Last updated
- 2006-07-27
Locations
52 sites across 7 countries: United States, Australia, France, Germany, Singapore, Spain, United Kingdom
Source: ClinicalTrials.gov record NCT00043966. Inclusion in this directory is not an endorsement.